Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,122,925
  • Shares Outstanding, K 98,849
  • Annual Sales, $ 89,150 K
  • Annual Income, $ 8,000 K
  • EBIT $ -91 M
  • EBITDA $ -98 M
  • 60-Month Beta 0.82
  • Price/Sales 11.63
  • Price/Cash Flow N/A
  • Price/Book 7.02

Options Overview Details

View History
  • Implied Volatility 91.71% (+12.74%)
  • Historical Volatility 91.25%
  • IV Percentile 70%
  • IV Rank 29.66%
  • IV High 191.78% on 11/19/25
  • IV Low 49.51% on 07/11/25
  • Expected Move (DTE 24) 1.62 (14.64%)
  • Put/Call Vol Ratio 4.07
  • Today's Volume 76
  • Volume Avg (30-Day) 371
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 13,057
  • Open Int (30-Day) 20,119
  • Expected Range 9.42 to 12.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 5
  • High Estimate -0.24
  • Low Estimate -0.48
  • Prior Year 0.52
  • Growth Rate Est. (year over year) -178.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.56 +45.90%
on 11/24/25
11.50 -4.09%
on 12/22/25
+3.44 (+45.32%)
since 11/21/25
3-Month
6.66 +65.62%
on 11/21/25
11.70 -5.73%
on 10/10/25
+1.09 (+10.97%)
since 09/23/25
52-Week
6.66 +65.62%
on 11/21/25
18.90 -41.64%
on 06/27/25
-0.17 (-1.52%)
since 12/23/24

Most Recent Stories

More News
ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves...

SPRY : 11.03 (-2.90%)
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

$32.5 million in revenue, including $31.3 million in  neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and...

SPRY : 11.03 (-2.90%)
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

Offers no-hassle, free  virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to eligible patients...

SPRY : 11.03 (-2.90%)
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray) Oral presentation to report results...

SPRY : 11.03 (-2.90%)
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients...

SPRY : 11.03 (-2.90%)
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of  neffy ® (epinephrine nasal spray) Oral presentation reports about 9 out...

SPRY : 11.03 (-2.90%)
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better...

SPRY : 11.03 (-2.90%)
2 Penny Stocks That Wall Street Believes Can Soar Over 200%

Penny stocks are highly volatile, but some of them have the potential to deliver outsized returns.

SPRY : 11.03 (-2.90%)
ADVM : 4.36 (+2.35%)
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical...

SPRY : 11.03 (-2.90%)
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in Japan for adults and children ( > 15 kg) living with severe allergic reactions...

SPRY : 11.03 (-2.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 11.86
2nd Resistance Point 11.59
1st Resistance Point 11.31
Last Price 11.03
1st Support Level 10.76
2nd Support Level 10.49
3rd Support Level 10.21

See More

52-Week High 18.90
Fibonacci 61.8% 14.22
Fibonacci 50% 12.78
Fibonacci 38.2% 11.34
Last Price 11.03
52-Week Low 6.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar